Grace Therapeutics (GRCE) Long-Term Deferred Tax (2024 - 2026)
Grace Therapeutics (GRCE) posted Long-Term Deferred Tax of $51.1 million for Q1 2026, up 18.78% sequentially from $43.0 million in Q1 2025, and up 18.78% YoY from $43.0 million in Q1 2025.
Grace Therapeutics (GRCE) Long-Term Deferred Tax (2024 - 2026) Analysis & Trends
Grace Therapeutics has reported Long-Term Deferred Tax for 3 years, with the latest figure at $51.1 million in Q1 2026.
- Quarterly Long-Term Deferred Tax rose 18.78% year-over-year to $51.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $51.1 million (up 18.78% YoY) and the FY2026 annual result came in at $51.1 million, up 18.78% from the prior year.
- Long-Term Deferred Tax improved to $51.1 million in Q1 2026 per GRCE's latest filing, from $43.0 million in the prior quarter.
- Over five years, Long-Term Deferred Tax peaked at $51.1 million in Q1 2026 and troughed at $5.9 million in Q1 2024.
- A 3-year average of $33.3 million and a median of $43.0 million in 2025 frame the typical range for Long-Term Deferred Tax.
- The sharpest annual moves came in 2025 and 2026: Long-Term Deferred Tax surged 635.25% in 2025, then climbed 18.78% in 2026.
- Over 3 years, Long-Term Deferred Tax stood at $5.9 million in 2024, then soared by 635.25% to $43.0 million in 2025, then increased by 18.78% to $51.1 million in 2026.
- According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $51.1 million, $43.0 million, and $5.9 million for Q1 2026, Q1 2025, and Q1 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Grace Therapeutics | 37.04 Mn | 37.04 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 51.13 Mn |
| Mar 31, 2025 | 43.05 Mn |
| Mar 31, 2024 | 5.86 Mn |